SecBot SecBot
8-K ·Filed May 6, 2026

ELAN

Elanco Animal Health Inc
BULLISH
Impact 8/10
Horizonweeks Processed6mo ago SEC0001739104-26-000027
8-K Item 2.02: Earnings release
Actionable Insight ▲ Bullish

The beat-and-raise quarter with broad-based growth across all species and accelerating innovation momentum is a strong positive catalyst. Watch for Q2 guidance ($1.30-$1.325B revenue, $0.25-$0.28 adjusted EPS) as a near-term check on execution. The improved net leverage target (3.0x-3.2x) and Elanco Ascend savings trajectory support further margin expansion. Monitor Befrena commercialization in Q2 and the AHV International integration.

DirectionBullish
Confidencehigh
Horizonweeks

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$26.14
T+0 close · May 6, 2026 · via day close
Latest settled
+1.23%
T+60 · $26.46
Vs SPY
+0.16%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 6 $26.14entry
  2. T+1 · 6mo ago −8.38%α −8.05% · $23.95
  3. T+5 · 6mo ago −18.01%α −19.14% · $21.43
  4. T+20 · 6mo ago −6.00%α −8.78% · $24.57
  5. T+60 · 4mo ago +1.23%α +0.16% · $26.46

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Elanco reported Q1 2026 adjusted EPS of $0.40, beating the $0.34 consensus by 17.6%, on revenue of $1.371B (+15% YoY, +10% organic constant currency), exceeding the $1.28B consensus. The company raised full-year 2026 guidance across all key metrics: revenue to $5.01-$5.085B, adjusted EBITDA to $975M-$1.005B, and adjusted EPS to $1.03-$1.09, driven by accelerating innovation portfolio momentum (Zenrelia blockbuster, Credelio Quattro share gains) and Elanco Ascend productivity savings.

Key Financial Metrics

EPS
$0.40
est $0.34 · +17.6%
Revenue
$1.4B
est $1.3B · +7.1% · +15.0% YoY
Rating
strong beat
Guidance
$5,010M to $5,085M
raised
Gross Margin
57.3%

Key Facts

  • Q1 2026 revenue $1.371B, +15% YoY reported, +10% organic constant currency, vs consensus $1.28B
  • Adjusted EPS $0.40 vs consensus $0.34 (+17.6% beat) and vs $0.37 in Q1 2025 (+8% YoY)
  • Adjusted EBITDA $334M, +21% YoY; margin expanded to 24.5% from 23.1%
  • Raised FY2026 guidance: revenue to $5.01-$5.085B (from $4.95-$5.02B), adjusted EBITDA to $975M-$1.005B, adjusted EPS to $1.03-$1.09
  • Innovation revenue target raised to $1.2B; Zenrelia reached trailing 4-quarter blockbuster status
  • Net leverage ratio improved to 3.5x from 3.6x at year-end 2025; year-end target improved to 3.0x-3.2x
  • Closed acquisition of AHV International on April 30, 2026

Financial Impact

Q1 revenue beat consensus by ~$91M (7.1%); adjusted EPS beat by $0.06 (17.6%)

revenueadjusted EPSadjusted EBITDAnet leverage

Risk Factors

  • GAAP net income declined 15% YoY to $57M due to higher interest expense and restructuring charges
  • Adjusted gross margin contracted 40bps to 57.0% on product mix and inflation
  • Operating cash flow was only $13M in Q1, though improved from -$4M a year ago
  • Elevated net debt of $3.335B and leverage of 3.5x still above long-term target of 2.0x-2.5x

Market Snapshot

Exchange
NYSE
Sector
Pharmaceutical Preparations
Analyst Consensus
91% bullish (23 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001739104-26-000027
Document: elan-20260506.htm0001739104-26-000027
Document: 0001739104-26-000027-index-headers.html0001739104-26-000027
Document: 0001739104-26-000027-index.html0001739104-26-000027
Document: 0001739104-26-000027.txt0001739104-26-000027
8-K Data (Synthetic)0001739104-26-000027

Track record

19 reports on ELAN

Performance horizon

4 of 5 bullish or bearish reports moved the stock their way by T+60. Best: +15.03% at T+5 after the May 19, 2026 report. 8 of 9 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $26.68 Now $26.41 −1.01% settles Feb 12
  2. Nov 12, 20264d ago SC 13G/A Neutral 2/10 Entry $26.78 Now $26.41 −1.38% settles Feb 11
  3. Nov 6, 202610d ago 8-K Bullish 6/10 Entry $25.74 Now $26.41 +2.60% settles Feb 4
  4. Nov 5, 202611d ago SC 13G/A Neutral 3/10 Entry $23.68 Now $26.41 +11.53% settles Feb 3
  5. Nov 3, 202613d ago 3 Neutral 1/10 Entry $25.31 Now $26.41 +4.35% settles Feb 2
  6. Oct 14, 20264w ago Institutional Cluster Bullish 4/10 Entry $23.54 Now $26.41 +12.19% settles Jan 12
  7. Sep 11, 20269w ago Press Release Neutral 1/10 Entry $23.17 Now $26.41 +13.98% settles Dec 7
  8. Aug 21, 202612w ago Insider Cluster Bullish 6/10 Entry $24.42 Now $26.41 +8.15% settles Nov 17
  9. Aug 21, 202612w ago Insider Cluster Bullish 4/10 Entry $24.42 Now $26.41 +8.15% settles Nov 17
  10. Aug 18, 202612w ago Insider Cluster Bullish 4/10 Entry $24.50 to $26.50 Now $26.41 +7.80% ▲ +8.16% +9.72% vs SPY
Showing 10 of 19

US Market Status

Market Closed · Opens in 5h 39m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 6, 2026